Menu Search
Equities

Hangzhou AGS MedTech Co Ltd

688581:SHH

Hangzhou AGS MedTech Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)62.00
  • Today's Change-1.98 / -3.09%
  • Shares traded969.19k
  • 1 Year change-23.25%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Hangzhou AGS MedTech Co Ltd grew revenues 37.09% from 371.11m to 508.75m while net income improved 49.87% from 144.96m to 217.24m.
Gross margin71.52%
Net profit margin46.01%
Operating margin54.00%
Return on assets11.71%
Return on equity12.26%
Return on investment12.26%
More ▼

Cash flow in CNYView more

In 2023, Hangzhou AGS MedTech Co Ltd increased its cash reserves by 822.66%, or 1.74bn. Cash Flow from Financing totalled 1.60bn or 314.02% of revenues. In addition the company generated 221.45m in cash from operations while cash used for investing totalled 76.79m.
Cash flow per share--
Price/Cash flow per share--
Book value per share28.53
Tangible book value per share28.30
More ▼

Balance sheet in CNYView more

Hangzhou AGS MedTech Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio20.07
Quick ratio19.56
Total debt/total equity0.003
Total debt/total capital0.003
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 49.87%.
Div yield(5 year avg)--
Div growth rate (5 year)--
Payout ratio (TTM)30.69%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		42.49
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.